Photodynamic therapy (PDT) is an innovative and attractive modality, which is potentially beneficial for the treatment of a number of cancers either as stand-alone or as adjuvant treatment. Currently PDT is in a Phase III clinical trial for the treatment of intracanial neoplasms using Photofrin as the Photosensitizer (Muller et al). Selectivity of PDT treatment is based on the inherent selectivity of the photosensitizer towards malignant cells and light fluence distribution within the tissue of a monochromatic source that matches the absorption spectrum of the sensitizer. However, there is currently, no individualized dosimetry or monitoring system for treatment progress using either a direct or indirect biological responses, available, which would enable the physician to modify the treatment or repeat it while photosensitizer in under treated tissue is still available.
|